Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas

American Journal of Pathology

Volumn 155, Issue 2, 1999, Pages 441-452

  Streit, Michael ^a   Velasco, Paula ^a   Brown, Lawrence F ^b   Skobe, Mihaela ^a   Richard, Lisa ^a   Riccardi, Lucia ^a   Lawler, Jack ^b   Detmar, Michael ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CD36 ANTIGEN; THROMBOSPONDIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

EID: 0032770860     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65140-1     Document Type: Article

References (47)

1. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364
2. Brown LF, Detmar M, Claffey K, Nagy JA, Feng D, Dvorak AM, Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. Exs 1997, 79:233-269
3. Ferrara N: The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995, 36:127-137
4. Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo K-T, Manseau EJ, Dvorak HF: Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996, 56: 172-181
5. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE: Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 1997, 3:1222-1227
6. Iruela-Arispe M, Bornstein P, Sage H: Thrombospondin exerts an antiangiogenic effect on cord formation by endothelial cells in vitro. Proc Natl Acad Sci USA 1991, 88:5026-5030
7. Volpert OV, Tolsma SS, Pellerin S, Feige JJ, Chen H, Mosher DF, Bouck N: Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun 1995, 217:326-332
8. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y Sage EH, Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79:315-328
9. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285
10. Bornstein P: Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol 1995, 130:503-506
11. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N: Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993, 122:497-511
12. Varani J, Carey TE, Fligiel SEG, McKeever PE, Dixit VM: Tumor type-specific differences in cell-substrate adhesion among human tumor cell lines. Int J Cancer 1987, 39:397-403
13. Varani J, Dixit VM, Fligiel SE, McKeever PE, Carey TE: Thrombospondin-induced attachment and spreading of human squamous carcinoma cells. Exp Cell Res 1986, 167:376-390
14. Riser BL, Varani J, O'Rourke K, Dixit VM: Thrombospondin binding by human squamous carcinoma and melanoma cells: relationship to biological activity. Exp Cell Res 1988, 174319-329
15. Yabkowitz R, Mansfield PJ, Dixit VM, Suchard SJ: Motility of human carcinoma cells in response to thrombospondin: relationship to metastatic potential and thrombospondin structural domains. Cancer Res 1993, 53:378-387
16. Albo D, Arnoletti JP, Castiglioni A, Granick MS, Solomon MP, Rothman VL, Tuszynski GP: Thrombospondin (TSP), and transforming growth factor β 1 (TGF-β) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production, and stimulate tumor cell attachment in vitro: Biochem Biophys Res Commun 1994, 203:857-865
17. Wang TN, Qian XH, Granick MS, Solomon MP, Rothman VL, Tuszynski GP: The effect of thrombospondin on oral squamous carcinoma cell invasion of collagen. Am J Surg 1995, 170:502-505
18. Albo D, Berger DH, Wang TN, Hu X, Rothman V, Tuszynski GP: Thrombospondin-1 and transforming growth factor-β1 promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system. Surgery 1997, 122:493-499
19. Albo D, Berger DH, Tuszynski GP: The effect of thrombospondin-1 and TGF-β1 on pancreatic cancer cell invasion. J Surg Res 1998, 76:86-90
20. Castle V, Varani J, Fligiel S, Prochownik EV, Dixit V: Antisensemediated reduction in thrombospondin reverses the malignant phenotype of human squamous carcinoma. J Clin Invest 1991, 87:1883-1888
21. Tuszynski GP, Nicosia RF: The role of thrombospondin-1 in tumor progression and angiogenesis. Bioessays 1996, 18:71-76
22. Zabrenetzky V, Harris CC, Steeg PS, Roberts DD: Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int J Cancer 1994, 59:191-195
23. Campbell SC, Volpert OV, Ivanovich M, Bouck NP: Molecular mediators of angiogenesis in bladder cancer. Cancer Res 1998, 58:1298-1304
24. Wight TN, Raugi GJ, Mumby SM, Bornstein P: Light microscopic immunolocation of thrombospondin in human tissues. J Histochem Cytochem 1985, 33:295-302
25. Rheinwald JG, Beckett MA: Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas. Cancer Res 1981, 41:1657-1663
26. Richard L, Velasco P, Detmar M: A simple immunomagnetic protocol for the selective isolation and long-term culture of human dermal microvascular endothelial cells. Exp Cell Res 1998, 240:1-6
27. Detmar M, Brown LF, Berse B, Jackman RW, Elicker BM, Dvorak HF, Claffey KP: Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. J Invest Dermatol 1997, 108:263-268
28. Schmidt R, Streit M, Kaiser R, Herzberg F, Schirner M, Schramm K, Kaufmann C, Henneken M, Schafer KM, Thiel E, Kreuser ED: De novo expression of the α5β1-fibronectin receptor in HT29 colon-cancer cells reduces activity of C-SRC: increase of C-SRC activity by attachment on fibronectin. Int J Cancer 1998, 76:91-98
29. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685
30. 1: a potent inhibitor of experimental lung metastasis. Clin Exp Metastasis 1998, 16:427-435
31. Gorczyca W, Gong J, Darzynkiewicz Z: Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res 1993, 53:1945-1951
32. Gillies RJ, Didier N, Denton M: Determination of cell number in monolayer cultures. Anal Biochem 1986, 159:109-113
33. Detmar M, Brown LF, Schön MP, Elicker BM, Velasco P, Richard L, Fukumura D, Monsky W, Claffey KP, Jain RK: Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998, 111:1-6
34. Myoken Y, Kayada Y, Okamoto T, Kan M, Sato GH, Sato JD: Vascular endothelial cell growth factor (VEGF) produced by A-431 human epidermoid carcinoma cells and identification of VEGF membrane binding sites. Proc Natl Acad Sci USA 1991, 88:5819-5823
35. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP: CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997, 138:707-717
36. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD, Steeg PS: Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994, 54:6504-6511
37. Castle VP, Dixit VM, Polverini PJ: Thrombospondin-1 suppresses tumorigenesis and angiogenesis in serum- and anchorage-independent NIH 3T3 cells. Lab Invest 1997, 77:51-61
38. Sheibani N, Frazier WA: Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype, and suppresses their tumorigenesis. Proc Natl Acad Sci USA 1995, 92:6788-6792
39. Hsu SC, Volpert OV, Steck PA, Mikkelsen T, Polverini PJ, Rao S, Chou P, Bouck NP: Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res 1996, 56:5684-5691
40. Volpert OV, Lawler J, Bouck NP: A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci USA 1998, 95:6343-6348
41. Varani J, L RB, Hughes LA, Carey TE, Fligiel SE, Dixit VM: Characterization of thrombospondin synthesis, secretion and cell surface expression by human tumor cells. Clin Exp Metastasis 1989, 7:265-276
42. Castle VP, Ou X, O'Rourke K, Dixit VM: High level thrombospondin 1 expression in two NIH 3T3 cloned lines confers serum- and anchorage-independent growth. J Biol Chem 1993, 268:2899-2903
43. Quo N-h, Zabrenetzky VS, Chandrasekaran L, Sipes JM, Lawler J, Krutzsch HC, Roberts DD: Differential roles of protein kinase C and pertussis toxin-sensitive G-binding proteins in modulation of melanoma cell proliferation and motility by thrombospondin 1. Cancer Res 1998, 58:3154-3162
44. O'Reilly MS, Holmgren L, Chen C, Folkman J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996, 2:689-692
45. Stomski FC, Gani JS, Bates RC, Burns GF: Adhesion to thrombospondin by human embryonic fibroblasts is mediated by multiple receptors and includes a role for glycoprotein 88 (CD36), Exp Cell Res 1992, 198:85-92
46. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Nail Acad Sci USA 1996, 93:14765-14770
47. 1 integrins. Proc Natl Acad Sci USA 1997, 94:13612-13617